Meeting
2019 Genitourinary Cancers Symposium
Angiogenic factor and cytokine analysis among patients with renal cell carcinoma treated with adjuvant VEGFR TKIs.
Authors
Wenxin Xu
Beth Israel Deaconess Medical Center, Boston, MA
Wenxin Xu , Maneka Puligandla , Naomi B. Haas , Keith Flaherty , Robert Uzzo , Janice P. Dutcher , Robert S. DiPaola , Rupal Satish Bhatt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 586)
DOI
10.1200/JCO.2019.37.7_suppl.586
Abstract #
586
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A randomized, double-blinded clinical trial of royal jelly intake for anticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors.
First Author: Yasuyoshi Miyata
Poster
2020 Genitourinary Cancers Symposium
Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
First Author: Rabbia Siddiqi
Poster
2019 ASCO Annual Meeting
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2017 ASCO Annual Meeting
Microvessel density as a prognostic marker in high-risk renal cell carcinoma.
First Author: Sarah A. Weiss